INTRODUCTION
Toxic shock syndrome (TSS) was originally described 10 years ago, in 1978 (167) . At that time, seven children (three males and four females) who had similar clinical and laboratory findings of acute fever, hypotension, multisystem involvement, and a rash which progressed to peeling of the hanis and feet in the six survivors were reported. Extensive laboratory evaluation failed to identify any conventional microbial etiology other than the isolation of Staphylococcus aureus from focal infections in two patients and other colonized sites in three others. These staphylococcal strains all reacted with group I bacteriophages and produced an apparently new epidermal toxin. After laboratory exclusion of other potential microbial etiologies, this apparently unique group of clinical findings was described as "toxic shock syndrome associated with phage group I staphylococci." At that time it was apparent from a review of the literature that similar cases associated with staphylococcal infection had been reported as far back as 1927 (167, 169) .
In 1980, TSS was recognized with increasing frequency in the United States and was epidemiologically associated initially with menstruation in young women and soon thereafter with tampon usage (47, 153) . In September 1980, an epidemiologic report of the association of TSS specifically with one brand of tampon (Rely) (141) resulted in its removal from the market and a general public impression (albeit erroneous) that TSS was solely a tampon-related disease (56, 141, 168 (12, 149) ; subsequently, these proteins were confirmed to be one and the same and thereafter have been called toxic shock syndrome toxin 1 (TSST-1) (23, 42, 136) .
Extensive investigations of the epidemiology of TSS and the chemical and biological features of TSST-1 resulted in the general impression that the pathogenesis of TSS was straightforward (13, 14, 53, 136, 142, 143, 145, 147) . However, recent studies suggest a more complex microbe-host relationship. Further epidemiologic investigations have shown that the incidence of TSS did not diminish in some states after the Rely tampon was removed from the market (114, 115, 177) and, in fact, increased in another (123) . In addition, many nonmenstrual cases of TSS were described in increasing numbers in males as well as females (8, 110, 132, 133, 177, 185) , and not all of the S. aureus strains isolated TOXIC SHOCK SYNDROME 433 from these patients produced TSST-1 (45, 84, 132) . Animal model studies suggested that under some circumstances TSST-1 was not particularly toxic (127) ; subsequently, other exoproteins have been described (including the previously described epidermal toxin) which may also play roles in the pathophysiology of TSS (41, 65, 145, 151, 170, 173, 192 Thus, after 10 years, TSS is still an important disease with many interesting clinical, epidemiologic, and microbiologic features. Concepts are evolving which may explain the apparent discrepancies between past assumptions and current observations.
CLINICAL FEATURES
Signs and Symptoms TSS can occur in patients of any age, but it is commonly seen in young adults and children who are otherwise healthy (177) . The typical patient presents with fever, rash, and toxicity often progressing to hypotension (31, 36, 47, 48, 61, 62, 107, 153, 167, 169, 178, 180) . These presenting symptoms have usually been preceded by a several-day history of watery diarrhea, nausea and vomiting, sore throat, and myalgia. At the time of presentation, the patients may have orthostatic hypotension or overt shock; hypotension may also be manifested by a decreased urine output and poor capillary refill.
On physical examination there may be signs of dehydration, especially if fever, vomiting, and diarrhea have persisted for a number of days without adequate fluid intake. In extreme cases when the patient has severe hypotension, the rash may not be apparent until the blood pressure is appropriately reestablished (186) . It usually presents as an erythema over the total body, is more prominent on the trunk, and has many features similar to that of scarlet fever, although it tends not to be as intense and does not ordinarily feel rough. The rash is usually not painful or pruritic and rarely (compared with scalded skin syndrome) forms bullous lesions. A Nikolsky sign is rarely present. If the patient survives, a unique peeling is noted to occur in week 2 to 4 on the finger and toe tips, progressing to the palms and soles.
Most patients present with conjunctival hyperemia (without purulent exudate) and pharyngeal hyperemia with a strawberry (or raspberry) tongue. Some may be jaundiced. Patients may be semicomatose without focal neurologic signs and may have other signs and symptoms related to a generalized, toxic (or hypotensive) effect on other organ systems (48) .
Laboratory Findings
Laboratory examinations are consistent with an acutely ill, febrile patient with poor organ perfusion. The leukocyte count is usually elevated, and the differential count shows a shift to the left with increased band forms and metamyelocytes. The platelet count may be decreased with additional signs of disseminated intravascular coagulation, although overt bleeding is uncommon. Liver enzymes may be elevated. The bilirubin may be increased, and often the direct (conjugated) component is predominant. Serum creatinine phosphokinase levels are often dramatically elevated, consistent with the symptom of myalgia. The urine analysis is usually abnormal with a cellular sediment; creatinine and blood urea nitrogen are often increased. These findings may represent a prerenal effect of dehydration and hypotension but may progress to acute tubular necrosis unless the blood pressure is re-established quickly. Serum electrolytes may be variously affected depending on the amount and type of prior fluid intake; however, serum calcium and phosphate are often abnormally low (33; M. A. Wagner, D. H. Batts, J. M. Colville, and C. B. Lauter, Letter, Lancet i: 1208, 1981 ). Blood cultures are usually (but not always) negative for S. aureus; however, focal sites of infection usually yield the causative organism (98) .
Definition and Differential Diagnosis A strict definition for severe TSS was jointly created by the Centers for Disease Control and several investigators in 1980 (153) , although various other definitions have been used (169) . The collaborative definition has been most widely utilized and more recently shown to be quite specific in excluding other illnesses which might fit into the differential diagnosis (189) . To have a confirmed case of TSS, a patient must have all major criteria and three or more minor criteria, besides exclusionary evidence that no other disease is present. Major criteria (must have all) are a fever, with temperature of .102'F (38.80C); a rash (diffuse, macular erythroderma); skin desquamation, usually 1 to 2 weeks after onset of illness and particularly of the palms of the hands and the soles of the feet; and hypotension, with systolic blood pressure of <90 mm Hg for adults or below the fifth percentile by age for children of <16 years of age, or orthostatic syncope. Minor criteria (involvement of three or more of the following organ systems) include gastrointestinal involvement (vomiting or diarrhea at onset of illness); muscular involvement (severe myalgia or creatinine phosphokinase level more than twice the upper limit of normal); mucous membrane involvement (vaginal, oropharyngeal, or conjunctival hyperemia); renal (blood urea nitrogen and creatinine levels more than twice the upper limit of normal, or >5 per high-power field in the absence of a urinary tract infection); hepatic leukocytes (total bilirubin, serum glutamic oxaloacetic transaminase, and serum glutamic pyruvic transaminase more than twice the upper limit of normal); hematologic involvement (platelets, <100,000/mm3); and/or central nervous system involvement (disorientation or alterations in consciousness without focal neurological signs when fever and hypotension are absent). Excluding data (negative results on the following tests, if obtained) are cultures of the throat (for group A streptococcus), blood, or cerebrospinal fluid (except S. aureus) and serologic tests for Rocky Mountain spotted fever, leptospirosis, or measles. Menstruation does not play a role in the diagnosis. A focus of staphylococcal infection is not required, nor is S. aureus isolation from any site required.
There is no question that TSS of lesser severity likely occurs often (10, 61, 155, 161, 179, 189) . Probable cases include those patients who are missing one of the major or minor criteria without any other explanation for their illness. The severity of multisystem involvement seems to correlate with the degree of hypotension (48) . Nonetheless, the strict definition identifies patients who need hospitalization and are most likely to benefit from aggressive therapy. Cases of less severe TSS may respond to early therapy and never require hospital admission. To make accurate observations about the epidemiology, microbiology, and clinical treatment of TSS, the strict definition has been very important in ensuring that most cases so identified truly have a single syndrome. VOL. 1, 1988 The differential diagnosis of TSS includes her febrile illnesses associated with rash or hypotension or both (167, 189) . These include bacterial sepsis, meningococcemia, streptococcal scarlet fever (9, 43) , staphylococcal scalded skin syndrome, leptospirosis, measles, enterovirus infection with myocarditis, Rocky Mountain spotted fever, and severe drug eruption (16) (e.g., Stevens-Johnson syndrome or toxic epidermal necrolysis [172] ). The strict case definition for TSS usually excludes these other illnesses when applied rigidly (189) This probably is related to the phenotypic characteristics of these S. aureus strains, which differ significantly from characteristics of other S. aureus strains (173) . When the clinical diagnosis of TSS is suspected, it is very important to surgically explore all wounds thoroughly to make sure any focus of infection has been thoroughly drained, successful therapy of TSS being often dependent on complete drainage.
Outcome and Sequelae Approximately 2 to 5% of patients with TSS may die, but most patients respond to appropriate therapy (171, 180) . A few will suffer from poor arterial perfusion, especially of the distal extremities, and may develop dry gangrene and loss of digits or even distal parts of extremities. Most patients will develop the typical desquamation of the fingers and toes beginning 2 to 3 weeks after onset of the illness and subsequently will experience creasing of the fingernails and hair loss, both of which resolve in time. Persistent neuropsychological sequelae have been reported (140) Early studies of TSS in menstruating women showed a recurrence rate as high as 60% over the ensuing 6-month period (48, 75) . It has been shown that this risk of recurrence can be markedly reduced by initial treatment with antistaphylococcal therapy and avoidance of tampon use (48 (79, 80, 186) . In a few there has been evidence of epidermal separation (58) , but more commonly, there is a mild lymphocytic dermal perivasculitis (5, 79, 80, 99, 116) , and some think that the skin pathology is typical and diagnostic of TSS (79) . In most cases, evidence of inflammation is uncommon. Although TSS behaves like a vasculitic disease, there is very little evidence of intravascular inflammation, and, in spite of the high leukocyte count and shift to the left, the mild perivascular inflammation tends to be lymphocytic rather than mediated by polymorphonuclear neutrophils. The typical signs of shock, in the lung, kidney, and liver, are not accompanied by significant inflammatory lesions except on the mucous membranes of the esophagus and vagina (1, 19, 99, 116, 188) . Although vaginal ulcerations have been seen in TSS patients who were using tampons, they also have been found in patients who were not using tampons, suggesting that the ulceration may be the result of the'disease rather than its cause (99) .
EPIDEMIOLOGY Association with Menstruation and Tampon Use
In January 1980, prior to the association of TSS with menstruation and subsequently with tampon use, a summary of all cases prospectively reported by investigators in and around Colorado was made (168) . There were 35 cases, of which 10 were male and 25 were female. The females were significantly older than the males, with an average age of 20.2 years. Seven of 10 of the males had clear-cut evidence of focal staphylococcal infection as compared with 2 of 22 females. The 20 remaining females gave a history of a vaginal discharge that grew S. aureus. Two-thirds .pf the isolated staphylococci reacted with group I staphylococcal bacteriophages and produced the epidermal toxin originally described in 1978 (167) . These data clearly demonstrated a female predominance (although males were also affected) and suggested that affected females were more likely to be older than males with TSS. In males, there was a strong association with focal staphylococcal infections, while in females the data suggested a vaginal association. These data are important because'they reflected a selection of cases which occurred prior to any public suggestion of a relationship with menstruation and tampon use, which may have biased subsequent reports.
In (8, 63, 132, 133) , often with increased frequency (122, 177) compared with the early epidemiologic reports which may have selectively focused on females who were menstruating (47, 153) . High-risk groups appear to be postpartum women (24, 30, 35, 67, 68, 187) -and patients with surgical wound infections (8, 25, 57, 187) , focal staphylococcal infections (175) , and nasal surgery (78, 85, 162, 166 Incidence It is difficult to determine the true incidence of TSS in populations for which reliance is placed on passive reporting (29, 120, 159) . Davis and Vergeront demonstrated that self-reporting of TSS cases was encouraged by frequent newspaper coverage of the topic and seemed to diminish when articles on the subject were infrequent (49) . A number of the early studies on the epidemiology of TSS relied on passive case reporting (47, 153) and came to the conclusion that its incidence decreased after removal of Rely tampons from the market (134 (123) . In several studies, TSS incidence was actually found to rise in the late 1970s prior to the introduction of Rely tampons (102, 123, 177) .
In Colorado, the maximal incidence of TSS was reported to be 15.8 cases per 100,000 woman years and 9.1 per 100,000 per year for the total population (177) (177) . There may also be a bias in diagnosis and reporting of TSS cases when they occur in male patients or women who are menstruating and not using tampons (177) . Clinicians may continue to inappropriately use menstruation and tampon use as a marker for TSS, while the case definition clearly avoids such an association.
High-Risk Groups
It is important to recognize TSS as an illness which affects a population that is not limited to menstruating young women. TSS has been confirmed in patients from newborns and children (26, 32, 35, 64, 67, 190) to geriatrics. The highest risk is still in children and young adults (177), presumably because they are more likely to represent individuals who have not previously encountered or developed immunity to the involved toxin(s). Table 1 summarizes the individuals who should be considered at risk of TSS based on epidemiologic and clinical experience. There is no question that a menstruating woman who is using a tampon or other inserted vaginal foreign body is at some increased risk for TSS. The risk just for menstruation ranges from 1 to 16 cases per 100,000 woman years. Certainly for any menstruating woman presenting with a fever along with associated symptoms of hypotension, rash, or conjunctival hyperemia, TSS should be included in the differential diagnosis. The same is true for women who are using barrier contraception or are postpartum.
It is important to emphasize, however, that females are not the only individuals at risk of TSS and that males as well as females are in the high-risk groups associated with surgical wound infections or known S. aureus infections. Individuals of either sex in these groups who have any symptoms of fever, hypotension, or rash should be considered at risk of TSS. Finally, for patients of either sex with no known risk factor, TSS should still be considered in the differential diagnosis if patients present with fever and rash or hypotension with or without fever. A fascinating hypothesis suggested by Langmuir et al. is that the great fatal plague of Athens (430 to 420 B.C., the so-called Thycydides syndrome) might have been due to an epidemic of TSS (97) . Subsequent data have confirmed the association of clinical TSS with certain strains of S. aureus (3, 7, 47, 54, 153) . The majority of cases reported since 1978 have been associated with focal S. aureus wound infections or menstruation and tampon usage with S. aureus isolated from the patients' vaginal cultures. These S. aureus strains have characteristic phenotypes which differ from those of S. aureus strains in the general population (7, 173) . Further microbiologic evaluations of these strains have demonstrated at least one (and probably more) toxin (12, 23, 53, 149) which in certain (but not all) animal models reproduces many of the symptoms of TSS (127, 129, 151, 152, 165) . Most patients acquiring TSS do not have antibody against TSST-1 (21, 160) compared with the majority of individuals in the general population who have immunity and appear to be at lower risk of developing TSS (111, 138, 182) .
Finally, some patients have had multiple episodes of TSS associated with recurrent focal S. aureus infections (Todd, unpublished observations.) Such recurrences are well known in menstruating women who use tampons, and the use of antistaphylococcal antimicrobial therapy significantly reduces the risk of that recurrence (48 (93, 118) . One theory of the pathogenesis of TSS suggests that the presence of S. aureus strains along with endotoxin-producing organisms might result in an interaction of toxins (e.g., TSST-1 and endotoxin) to achieve a synergistic toxic effect in the host (149) . These effects are seen primarily in rabbits and chicken embryos (52) pretreated with endotoxin.
Therapeutic studies in rabbits withjust TSST-1 have shown a beneficial effect of polymyxin in one study (50) (12, 149) . Enterotoxin F was purified by using its biologic activity, emesis in monkeys, as a marker (12), and pyrogenic exotoxin C was purified based on its ability (synergistically with endotoxin) to cause fever and death in a rabbit model (149) . Both putative toxins were purified independently and, when compared by amino acid profile and immunologic cross-reactivity, appeared to be the same protein, which is now called TSST-1 (23, 42) .
Based on studies with purified protein, TSST-1 has a molecular weight of 22,000 to 24,000 and an isoelectric point of 7.2 (12, 23, 42, 130, 149) . It is commonly purified by initial ethanol precipitation, followed by isoelectric focusing (147) or ion-exchange and size exclusion column chromatography (12, 23, 149) . By common protein-staining techniques (e.g., Coomassie blue), it appears as a single band on denaturing polyacrylamide gels. Ouchterlony immunodiffusion with monospecific antisera to TSST-1 shows a single line of identity. In some preparations, however, more sensitive staining techniques (e.g., a silver stain) show higher-molecular-weight bands in addition to the primary band; and when Coomassie blue followed by silver staining is used ( (7) . In one phenotypic study, protease activity and TSST-1 production correlated strongly with each other and with TSS-associated S. aureus strains (173) . This protease activity has been shown to be due to the type II (thiol) protease (174 
Effects of Growth Conditions
Because of the marked interest in a possible relationship of tampons to the production of toxins mediating TSS, many studies have been performed to assess the growth conditions which might affect TSST-1 production in vitro. Various in vitro tampon models have been developed in an attempt to clarify the mechanism of the epidemiologically noted relationship of TSS and tampon use. Initially, it was proposed that the carboxymethyl cellulose component of Rely tampons might produce glucose upon breakdown with cellulose. Glucose then could be used as an energy source that would permit the increased growth of S. aureus strains in vivo and theoretically increase toxin production (164) . As S. aureus does not produce a cellulose, it was postulated that other vaginal microflora might facilitate the necessary breakdown of carboxymethyl cellulose. This theory has not been substatitiated (154) and, in fact, the use of increased glucose in the growth medium has actually been shown to decrease TSST-1 production (145).
Similar to other S. aureus proteins, the optimal production of TSST-1 by TSS-related S. aureus strains requires certain in vitro growth conditions (145, 146, 176) . Organism growth is severely limited in anaerobic environments and at low pH (145, 176) . At a neutral pH with added oxygen, strains are able to grow actively and produce more TSST-1 (145, 146,   176 ). The addition of protein and 5% CO2 increases toxin and protease production further (176) , as well as hemolytic activity (30 It does appear that small amounts of magnesium are essential for organism growth and that high levels of magnesium may, in fact, suppress TSST-1 production. The original studies were performed in a defined chemical medium; however, in more complex media, magnesium seems to have less of a controlling effect (144, 176) . Although it has been postulated that the polyacrylate component in some highabsorbancy tampons may absorb magnesium and permit increased TSST-1 production, these effects are medium dependent and may not truly reflect conditions in the patient. Epidemiologic studies do not confirm an increased risk of polyacrylate-containing tampons independent of absorbency (15) .
The addition of human blood to several in vitro models has also variously affected TSST-1 production. In one study an artificial medium was constructed to match human menses; this medium was the most effective in increasing TSST-1 production and was not affected by the addition of human blood (J. J. Kirkland (103, 157) . Those patients with low antibody titers before the TSS episode may develop increased antibody titers to TSST-1 after the clinical illness. However, many patients show no rise in titer to TSST-1, even after multiple episodes of clinical disease (21, 37, 111, 160) . One study suggests that such patients may have a selective immunoglobulin G subclass deficiency (subclass 2 or 4) (38), while another demonstrated that TSST-1 is capable of suppressing B-cell responses in vitro (125) . These data suggest that TSST-1 is not the only toxin associated with TSS, that a lack of antibody is a risk factor in some patients, and that immunity does not develop readily to TSST-1, at least in patients who have clinical disease.
In serological and microbiological surveys, patients who have TSST-1-producing S. aureus strains in their nasal cultures also tend to have the highest level of anti-TSST-1 even though they have never had a history of TSS (86, 138) . In addition, it is clear that many patients become colonized with TSST-1-producing S. aureus strains and develop no clinical illness although they may develop high levels of anti-TSST-1 (138) . This is further evidence that the S. aureus strain needs to grow under specific clinical conditions that permit expression of the causative toxin(s), conditions not usually present in the nasopharynx (see Fig. 2 ).
One additional host variable may be important in some patients. Many of the patients at high risk of TSS have altered hormonal states (menstruation, postpartum, childhood) characterized by low levels of sex hormones. In one study, several menstrual age females with existing focal S.
aureus infections had the onset of tampon-associated TSS with the onset of menses (177) . Epidemiologic studies suggest that oral steroid contraception is associated with a decreased risk of TSS (112) and, anecdotally, steroids have been useful in preventing recurrences (106) . In one study, a defect in S. aureus 502A (not a TSS strain) neutrophil killing was noted to be menses associated. In addition, methylprednisolone has been shown to be effective in treating early clinical TSS (175) Although some level of genetic regulation is operative in TSST-1 production, it also appears that TSST-1-positive S. aureus strains have the potential for posttranslational modification of extracellular protein expression (Fig. 1) . Todd et al. demonstrated that most TSST-1-positive strains of S. aureus produce large amounts of the type II (thiol) protease (174) which is enhanced by the same conditions that encourage TSST-1 production in vitro (i.e., C02, oxygen, and neutral pH) (176 (143) . When combined with endotoxin, it produces fever and increased mortality in rabbits (148, 149) . In vitro it is a potent stimulator of interleukin-1 (11, 83, 117, 119) , interleukin-2 (108, 181) , and T-suppressor cells (124, 142, 181) and has also been shown to increase human neutrophil oxidative metabolism (66) . Recently, TSST-1 has been shown to stimulate the secretion of tumor necrosis factor, a potent substance which is a biologic mediator of shock (T. Ikejima (167) . Thereafter, it was shown that TSS-associated S. aureus strain filtrates were not particularly toxic when given intravenously in rabbits or chicken embryos (7, 52 (12) .
Since that time, many investigators have given purified TSST-1 to various species of animals with various results (127) . Bolus injection seems to have less reproducible effects than does continuous toxin exposure, which has been achieved in various ways. Currently, a popular model for TSS involves the use of New Zealand White rabbits with a subcutaneous (4, 129, 152) or intrauterine (51) reservoir. The injection of TSST-1 (or of TSST-1-producing S. aureus strains) into the reservoirs is sufficient to result in a clinical illness in the rabbits similar to TSS in humans (although no rash is seen), while isogenic strains not possessing the tst gene do not cause a similar illness (51, 128) 39, p. 39), as did the use of tampon material saturated with TSST-1 and endotoxin in mice (165) . In several studies young rabbits were less responsive to toxin than older ones, males were more susceptible than females (18), and estradiol given to susceptible animals mitigated the pathologic response (17).
Overall, TSST-1 alone seems to have little effect in mice, rats, hamsters, guinea pigs, and most monkeys, whereas some symptoms are seen in rabbits, goats, and baboons. Nonetheless, it is difficult to state that the latter animals represent a reliable model of TSS as TSST-1-negative strains isolated from patients with (and without) proven TSS may also cause TSS-like symptoms in rabbits, possibly related to independent enterotoxin (or other exoprotein) production (4; K. A. Kohrman, J. J. Kirkland, and P. J. Danneman, Abstr. Int. Symp. T.S.S. 1987, abstr. no. 38, p. 38). That S. aureus strains produce a wide number of extracellular products (e.g., alpha-toxin, leukocidin, epidermolytic toxin, and enterotoxins) which cause severe biologic effects in some animals makes it difficult to confirm that the symptoms noted in animals given TSST-1 or infected with TSST-1-producing strains are specific for TSS in humans. In addition, recent data suggesting that most TSST-1 preparations are not pure (Chow et al., Abstr. Int. Symp. T.S.S. 1987) raise the possibility that highly potent contaminants might contribute to the symptoms noted in animals. Nonetheless, most animal model data relating to the effects of TSST-1 strongly support its role as the most prominent toxin causing TSS.
PATHOGENIC MODEL
The above data raise many questions regarding the pathogenesis of TSS. In the early 1980s, the answers seemed simpler than they do now. Initially it was thought that TSS was caused solely by TSST-1 and that its production was enhanced by interaction with tampon materials in vivo. It is now clear that this initial concept is insufficient to fully explain our current understanding of the complexity of the biology of TSS-associated S. aureus strains. The evidence (183) . The pathogenesis of TSS requires exposure of a nonimmune individual to a toxin-producing S. aureus strain (Fig.  2) . To allow optimal production, these S. aureus strains must grow under conditions which promote toxin expression. These 
